New combo therapy shows promise for tough transplant complication
NCT ID NCT02340676
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 27 times
Summary
This study tested whether adding a low dose of the drug Interleukin-2 (IL-2) to a standard therapy called Extracorporeal Photopheresis (ECP) could help people with chronic graft-versus-host disease (cGVHD) that did not improve with steroids. cGVHD is a serious condition where donor immune cells attack the patient's body after a stem cell transplant. The trial included 25 participants and measured how many had a response after 16 weeks of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Insitute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.